Assertio (NASDAQ:ASRT - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $28.67 million for the quarter. Parties interested in listening to the company's conference call can do so using this link.
Assertio Trading Down 0.6 %
Shares of ASRT stock traded down $0.01 during trading on Thursday, hitting $0.81. 88,324 shares of the stock traded hands, compared to its average volume of 826,251. The firm has a market capitalization of $77.53 million, a P/E ratio of -1.11, a price-to-earnings-growth ratio of 3.25 and a beta of 0.81. Assertio has a 52-week low of $0.73 and a 52-week high of $1.80. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.01 and a quick ratio of 1.57. The firm's fifty day moving average price is $0.83 and its 200-day moving average price is $0.99.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on ASRT shares. StockNews.com raised shares of Assertio from a "hold" rating to a "buy" rating in a research report on Wednesday, November 13th. HC Wainwright restated a "buy" rating and set a $4.00 price target on shares of Assertio in a report on Monday, December 16th.
Read Our Latest Report on ASRT
About Assertio
(
Get Free Report)
Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
Further Reading
Before you consider Assertio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assertio wasn't on the list.
While Assertio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
